Company / R&D Expense
NeoGenomics Laboratories, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$37.1M
FY2025
5-year range
$21.9M / $37.1M
FY2021-FY2025
Trend
+19.0%
vs FY2024
Sector context
#89 of 110
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s r&d expense of $37M is lower than 81% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $3M in FY2018 to $37M in FY2025.
Based on SEC 10-K filings.
$37M in FY2025 with a 5-year CAGR of +35.1%.
Improved from $27M to $37M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +6.9%
- 5-Year CAGR
- +35.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 110This company $37.1M Sector average $298.2M
▼
-87.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +35.1%, indicating consistent growth.
- In FY2025, r&d expense increased 19.0% year-over-year.
- Ranks #89 out of 110 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.1M | +19.0% |
| FY2024 | $31.2M | +14.1% |
| FY2023 | $27.3M | -9.9% |
| FY2022 | $30.3M | +38.6% |
| FY2021 | $21.9M | +165.8% |
| FY2020 | $8.2M | -3.0% |
| FY2019 | $8.5M | +182.8% |
| FY2018 | $3.0M | -17.5% |
| FY2017 | $3.6M | -21.8% |
| FY2016 | $4.6M | +10.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026